DO IT Trial: vitamin D Outcomes and Interventions in Toddlers - a TARGet Kids! randomized controlled trial. by Maguire, Jonathon L et al.
UC Davis
UC Davis Previously Published Works
Title
DO IT Trial: vitamin D Outcomes and Interventions in Toddlers - a TARGet Kids! 
randomized controlled trial.
Permalink
https://escholarship.org/uc/item/70g1v897
Journal
BMC pediatrics, 14(1)
ISSN
1471-2431
Authors
Maguire, Jonathon L
Birken, Catherine S
Loeb, Mark B
et al.
Publication Date
2014-02-08
DOI
10.1186/1471-2431-14-37
 
Peer reviewed
eScholarship.org Powered by the California Digital Library
University of California
Maguire et al. BMC Pediatrics 2014, 14:37
http://www.biomedcentral.com/1471-2431/14/37STUDY PROTOCOL Open AccessDO IT Trial: vitamin D Outcomes and
Interventions in Toddlers – a TARGet Kids!
randomized controlled trial
Jonathon L Maguire1,2,3,4,7*, Catherine S Birken3,4,7, Mark B Loeb8, Muhammad Mamdani1,5, Kevin Thorpe1,6,
Jeffrey S Hoch5,7,9,10, Tony Mazzulli11,12, Cornelia M Borkhoff3,7, Colin Macarthur3,4, Patricia C Parkin3,4,7,
on behalf of the TARGet Kids! CollaborationAbstract
Background: Vitamin D levels are alarmingly low (<75 nmol/L) in 65-70% of North American children older than
1 year. An increased risk of viral upper respiratory tract infections (URTI), asthma-related hospitalizations and use
of anti-inflammatory medication have all been linked with low vitamin D. No study has determined whether
wintertime vitamin D supplementation can reduce the risk of URTI and asthma exacerbations, two of the most
common and costly illnesses of early childhood. The objectives of this study are: 1) to compare the effect of ‘high
dose’ (2000 IU/day) vs. ‘standard dose’ (400 IU/day) vitamin D supplementation in achieving reductions in laboratory
confirmed URTI and asthma exacerbations during the winter in preschool-aged Canadian children; and 2) to assess
the effect of ‘high dose’ vitamin D supplementation on vitamin D serum levels and specific viruses that cause URTI.
Methods/Design: This study is a pragmatic randomized controlled trial. Over 4 successive winters we will recruit
750 healthy children 1–5 years of age. Participating physicians are part of a primary healthcare research network
called TARGet Kids!. Children will be randomized to the ‘standard dose’ or ‘high dose’ oral supplemental vitamin D
for a minimum of 4 months (200 children per group). Parents will obtain a nasal swab from their child with each
URTI, report the number of asthma exacerbations and complete symptom checklists. Unscheduled physician visits
for URTIs and asthma exacerbations will be recorded. By May, a blood sample will be drawn to determine vitamin
D serum levels. The primary analysis will be a comparison of URTI rate between study groups using a Poisson
regression model. Secondary analyses will compare vitamin D serum levels, asthma exacerbations and the
frequency of specific viral agents between groups.
Discussion: Identifying whether vitamin D supplementation of preschoolers can reduce wintertime viral URTIs and
asthma exacerbations and what dose is optimal may reduce population wide morbidity and associated health care
and societal costs. This information will assist in determining practice and health policy recommendations related
to vitamin D supplementation in healthy Canadian preschoolers.
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Evidence from observational studies suggests that low
vitamin D levels may be implicated in two of the most
common health issues during early childhood: viral upper
respiratory tract infections (URTI) and asthma [1]. These
two conditions place an enormous burden on Canada’s
health care system and economy. Viral URTI and asthma
exacerbations combined make up over 30% of all emer-
gency department visits for children in Canada [2].
Data from our group [3] and others have repeatedly
demonstrated that most urban preschoolers living in
North America have vitamin D serum levels significantly
lower than values recommended by both the American
Academy of Pediatrics (AAP) and the Canadian Paediatric
Society (CPS) [4,5]. However, these guidelines are not
based on child health outcome data but on expert opin-
ion and extrapolation from adult outcomes. There are
no Canadian recommendations for vitamin D supple-
mentation of children older than 1 year. Furthermore, it
is not known whether vitamin D supplementation leads
to measurable improvement in child health outcomes
or what dose (or what vitamin D serum level) is needed
to maximize health outcomes in preschoolers.
Because of Canada’s northern latitude, understanding
vitamin D deficiency and associated health problems is
of critical importance to Canadian children and their
parents. Our goal is to close the key knowledge gaps in
the potential health consequences associated with low
vitamin D levels in young children [4-8]. We are currently
conducting a randomized controlled trial to test the effect
of high dose orally supplemented vitamin D (2000 IU/day)
versus standard dose vitamin D supplementation (400 IU/
day) during the wintertime on these common childhood
health outcomes in Canadian preschoolers. If vitamin D
supplementation of preschoolers makes even a small
contribution to improving these problems, measures to
increase vitamin D levels may significantly reduce popu-
lation wide morbidity and associated health service
costs.
We have developed a primary-care practice based
research network called TARGet Kids! to conduct obser-
vational and interventional studies in preschoolers to
improve child health outcomes through primary pre-
vention. TARGet Kids! is first primary care child health
research network in Canada dedicated to improving the
health of young children. TARGet Kids! represents an
innovative collaboration between child health researchers
in the Faculty of Medicine at the University of Toronto
and children’s primary care physicians (pediatricians and
family physicians) from the Department of Pediatrics and
the Department of Family and Community Medicine at
the University of Toronto to advance evidence-based
solutions to prevent some of today’s biggest childhood
health concerns (http://www.targetkids.ca). We haveleveraged existing TARGet Kids! infrastructure, collabora-
tions, research personnel and data management system to
carry out this randomized controlled trial to determine
whether wintertime high dose vitamin D supplementation
of preschoolers reduces two common and costly child
health outcomes, viral URTI and asthma exacerbations.
Biochemistry and sources of vitamin D
Vitamin D is a fat soluble steroid with two clinically
relevant metabolites: 25-hydroxyvitamin D and 1,25-
dihydroxyvitamin D [9,10]. While 1,25-dihydroxyvitamin
D is the active form, it is not reflective of vitamin D
stores. Circulating levels of 25-hydroxyvitamin D are re-
flective of vitamin D stores and is commonly measured
to determine vitamin D serum level [11].
Vitamin D can be synthesized in the skin by exposure
to sunlight or can be ingested from dietary sources [9].
When exposed to solar ultraviolet B radiation the skin
converts 7-dehydrocholesterol to vitamin D3 [12]. How-
ever, north of 42°N latitude, there is little production of
vitamin D from the skin between November and March
[13]. Therefore, in temperate climates where exposure to
sunlight is limited for a significant part of the year, vitamin
D levels fall dramatically during the winter and dietary
sources of vitamin D become extremely important for
avoiding deficiency [14]. Few foods aside from fatty fish,
which are not regularly consumed by preschoolers, nat-
urally contain vitamin D [1]. Data from the Canadian
Community Health Survey and other sources suggest
that the majority of vitamin D that preschoolers ingest
is from vitamin D fortified cow’s milk which contains
100 IU of vitamin D per cup [15-17]. Unfortunately, the
amount of cow’s milk that preschoolers typically drink
is insufficient to receive enough vitamin D to avoid
wintertime deficiency [3,17-20]. Further, efforts to in-
crease cow’s milk consumption in this population may
increase the prevalence of iron deficiency [21-25].
Recommended vitamin D serum levels and
supplementation for preschoolers
It is well established that 25-hydroxyvitamin D serum
levels above 50 nmol/L in children are sufficient to pre-
vent rickets [6]. Therefore, the American Academy of
Pediatrics (AAP) suggests that 25-hydroxyvitamin D
levels in children be above 50 nmol/L [4]. Data from
adults suggest that serum levels above 75 nmol/L are
required to minimize calcium resorption from bone and
maximize intestinal calcium absorption [26]. Therefore,
the Canadian Paediatric Society (CPS) suggests that op-
timal 25-hydroxyvitamin D level for children is above
75 nmol/L [5].
The recommended vitamin D dietary allowance (RDA)
for children older than 1 year has been set at 600 IU/day
by both Health Canada and the Institute of Medicine.
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vitamin D fortified cow’s milk per day (which includes
most preschoolers) [3,27] are unlikely to receive this
amount of dietary vitamin D, the AAP recommends rou-
tine vitamin D supplementation of 400 IU/day for all
children ingesting < 1000 ml/day of vitamin D-fortified
formula or cow’s milk [4]. The CPS has no recommenda-
tion for routine vitamin D supplementation for Canadian
children older than 1 year [5]. However, we have found
that 56% of our population is receiving 400 IU/day of sup-
plemental vitamin D [28,29]. To reflect the current AAP
recommendation and common practice in our population,
we chose 400 IU/day for the ‘standard dose’ arm.
Low vitamin D levels in North American children
There is consistent evidence, from both single center
studies [17,30,31] and national surveys [18,19,27], that
North American children older than 1 year have vitamin
D serum levels lower than AAP or CPS recommendations
(see Additional file 1). Data from the 2001–2004 National
Health and Nutrition Examination Survey (NHANES)
indicated that 70% of children 1 to 11 years had vitamin
D levels < 75 nmol/L [18,19]. Data from the 2007–2009
Canadian Health Measures Survey suggested that 51%
of children age 6–11 years had vitamin D levels < 75 nmol/L.
Studies of pre-school aged children from Boston (42°N),
Toronto (43°N), St. John’s (47°N), Calgary (51°N), Edmonton
(53°N) and Alaska (58-61°N) have all found significant
rates of vitamin D deficiency in infants and toddlers
using various definitions [15,17,30-32].
Potential child health consequences of low vitamin D
levels
Severe vitamin D deficiency (25-hydroxyvitamin D
level < 25 nmol/L) results in rickets [1], an irreversible
bowing of the long bones and deformity of the joints and
teeth with well described long term implications for skeletal
growth [11]. Important health policy recommendations
including vitamin D fortification of cow’s milk and universal
vitamin D supplementation of breast fed infants has
dramatically reduced the prevalence of rickets in North
America (estimated to be 2.9 cases per 100,000 children in
Canada) [33]. The more recent observation that the vitamin
D receptor (VDR) is expressed in many tissues in the body
in addition to the skeletal and endocrine systems has
suggested that vitamin D may be acting in other ways [9].
Population-based, retrospective cohort and case–control
studies have suggested that less severe vitamin D deficiency
(25–75 nmol/L) in children may be associated with several
other adverse health outcomes [34-41].
Viral upper respiratory tract infection
Viral upper respiratory tract infections (URTI) are the
most common infectious disease in North America [42].URTI is the most common reason for emergency depart-
ment visits and unscheduled outpatient visits in Canada
comprising 10% of emergency department visits for chil-
dren under 10 years of age [2,43]. Preschoolers have the
highest incidence of URTI of any age group, occurring 1–
2 times per month per child during the winter and higher
among children who attend daycare [42,44-49]. Influenza,
RSV and adenovirus, which collectively comprise 25% of
respiratory infections in children, are the most common
viruses that lead to febrile illness, acute otitis media, out-
patient visits and hospitalization [44,50]. Roughly 50% of
preschoolers with URTI are brought to medical attention
resulting in an additional outpatient physician visit every
2 to 3 months during the winter with 1% requiring
hospitalization [44,51]. Several groups have estimated
the direct and indirect costs of URTI in preschoolers to
be between $261 and $276 per URTI with influenza be-
ing the most costly virus, contributing $809 per URTI
[45,51]. The collective cost of URTI in children under 5
years of age has been estimated to be $1.8 billion annually
in the US [52]. Evidence supporting a causal connection
between low vitamin D serum levels and URTI comes
from multiple sources.
Temporality
Both vitamin D levels and viral URTI show a remarkably
similar seasonal oscillation. R. Edgar Hope-Simpson
hypothesized that a “seasonal stimulus” must affect the
pathogenesis of influenza and Cannel et al. hypothesized
that this seasonal stimulus may be related to seasonal
oscillation of vitamin D levels [53,54].
Biological plausibility
Basic science has uncovered the role of vitamin D on
the innate immune system [55]. The primary site for
human contact with respiratory viruses is the upper re-
spiratory tract mucosa [56]. Vitamin D is constitutively
converted to its active form 1,25-hydroxyvitamin D in
respiratory epithelium [57]. The mucosa of the upper
airway is protected from infection by a complex set of
peptides which have direct antimicrobial properties and
contribute to innate immunity [58]. These peptides in-
clude defensins and calethicidin which have direct
antiviral properties [59]. Furthermore, respiratory tract
macrophages are stimulated to produce these peptides
in vitro by the presence of 25-hydroxyvitamin D and
in vivo through vitamin D supplementation [60,61].
Epidemiologic association
Observational studies support an association between
viral infections and vitamin D levels in both adults and
children. A post hoc analysis of a 3-year RCT of vitamin
D supplementation for bone loss in 208 post-menopausal
African American women found that 26 patients in the
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having a URTI (P = 0.002) [62]. Based on data from
NHANESIII, the odds of having a recent URTI in
Americans 12 years of age or older was 25% higher for
people with 25-hydroxyvitamin D < 75 nmol/L relative
to those > 75 nmol/L [63]. Young male Finnish soldiers
with 25-hydroxyvitamin D levels below 40 nmol/L had
nearly double the number of absent days from duty due
to respiratory infections than soldiers with levels above
40 nmol/L [64]. In a prospective cohort study of 198
adults in Connecticut U.S., 25-hydroxyvitamin D con-
centrations > 95 nmol/L were associated with a two-fold
reduction in URTI over a single winter [65]. Based on
data from a New Zealand birth cohort, infants with 25-
hydroxyvitamin D levels in cord blood below 25 nmol/L
were at 2-fold higher risk of viral respiratory tract infec-
tion at 3 months of age than infants with cord blood
levels above 75 nmol/L [66].
Randomized controlled trial (RCT) evidence
To our knowledge, no RCT has examined the effect of
vitamin D supplementation on health outcomes in pre-
schoolers. Three RCTs have examined the effect of vita-
min D supplementation on URTI, two in adults and one
in older children. Li-Ng and colleagues randomized 162
adults to 2000 IU per day of vitamin D or placebo for 3
months during the winter in Long Island, NY U.S. and
recorded the frequency of URTI symptoms (without
laboratory viral confirmation) using a bi-weekly online
questionnaire. They found no difference in the incidence
of reported URTI between vitamin D and placebo groups
(48 URTIs vs. 50 URTIs, p = 0.57) [67]. As the authors
point out, the lack of effect may have resulted from a rela-
tively small difference in follow-up vitamin D levels in the
vitamin D (88 nmol/L) vs. placebo group (63 nmol/L). Re-
cently, Laaski et al. randomized 164 male Finnish army re-
cruits to 400 IU of vitamin D per day vs. placebo between
October and March [68]. Their primary outcome, mean
number of days absent from duty due to URTI in the vita-
min D vs. placebo group, demonstrated a trend towards
reduced absenteeism (2.2 days vs. 3.0 days, p = 0.096).
However, the dose of vitamin D chosen (400 IU per day),
may not have been sufficient to raise 25-hydroxyvitamin
D levels enough to impact significantly on viral URTI
(72 nmol/L in the intervention group vs. 51 nmol/L for
placebo). In the third trial, Urashima and colleagues
randomized 167 six to 15 year old schoolchildren to
1200 IU per day of vitamin D or placebo for four winter
months in Tokyo, Japan [69]. Their primary outcome,
laboratory confirmed Influenza A infection, showed a
statistically significant reduction in the vitamin D group
vs. control group (11% vs. 19%, p = 0.04). However, the
authors did not measure baseline or follow-up vitamin
D serum levels so it is unclear whether the positiveeffect was due to an increase in vitamin D levels. To
maximize our likelihood of finding a treatment effect
and keeping total vitamin D intake below the Tolerable
Upper Intake Level as recommended by Health Canada
(2500 IU/day for preschoolers) [70], we chose 2000 IU/
day for the ‘high dose’ arm.Asthma
Asthma is the most common chronic illness of childhood.
Preschoolers bear the highest burden of asthma which
affects 13% of children under 5 years of age compared
with 8% of children under 18 years in Ontario [71].
Asthma exacerbations are the most common non-surgical
cause for hospitalization of children in Canada, costing
the Canadian health care system over $300 million annu-
ally [71-74]. An association between vitamin D deficiency
and asthma exacerbation was initially proposed to explain
the observation that low vitamin D levels and asthma ex-
acerbations are both more common in temperate climates
and more common during the winter months [75,76]. Re-
cent basic science and epidemiological research has sup-
ported a connection between vitamin D serum levels and
asthma.Biological plausibility
In vitro studies have demonstrated that the VDR is present
in bronchial smooth muscle cells and that many asthma-
associated genes are expressed following stimulation of
lung tissue with vitamin D [77,78]. Case–control studies
have found associations between asthmatic individuals
and polymorphisms in the VDR and other vitamin D re-
lated genes [79-81].Epidemiologic association
Cross-sectional data from NHANESIII found a strong
correlation between airway resistance and vitamin D
levels in adults [82]. An examination of incident vitamin D
levels in a cohort of 1024 seven to ten year old American
children with mild-to-moderate asthma identified that
children with 25-hydroxyvitamin D levels below 75 nmol/L
had increased odds of emergency department visits and
hospitalizations relative to children with vitamin D
levels above 75 nmol/L over a period of 4 years (OR 1.5,
p = 0.01) [83]. Furthermore, two cross-sectional studies
of American and Costa Rican children suggested that
children with vitamin D levels below 75 nmol/L had
increased airway resistance and increased use of
inhaled and oral steroids relative to children with
vitamin D levels above 75 nmol/L [84,85]. Whether
these effects are due to vitamin D deficiency or are
mediated through a vitamin D related reduction in
viral URTIs is not clear.
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To our knowledge, no RCT has examined the effect of
vitamin D on asthma exacerbations in preschoolers. In the
trial by Urashima and colleagues of vitamin D supplemen-
tation of Japanese schoolchildren, asthma exacerbations
were measured as a secondary outcome [69]. They found
a statistically significant decrease in asthma exacerbations
in children receiving 1200 IU of vitamin D per day vs.
placebo (2 vs. 12 of 167 children, RR 0.17, p = 0.006).
Interestingly, the reduction in URTI was stronger
among children with asthma than those without (RR
0.17, p = 0.006) suggesting that the reduction in asthma
exacerbations may be mediated through reduced viral
URTIs among vitamin D supplemented children.
The objective of this paper is to serve as the first step
in knowledge dissemination of the DO IT Trial. The
current paper outlines the study protocol, explains the
rationale for the study design and selection of outcome
measures and documents some of the methodological
considerations.
Study objectives and hypotheses
The primary objective is to compare the effect of high
dose orally supplemented vitamin D (2000 IU/day) vs.
standard dose vitamin D supplementation (400 IU/day)
in achieving a reduction in laboratory confirmed viral
URTI during the winter in healthy preschoolers 1 to 5
years of age. We hypothesize that preschoolers supple-
mented with 2000 IU/day will have a reduction in
wintertime viral URTI.
Secondary objectives include comparing high dose
(2000 IU/day) vs. standard dose (400 IU/day) vitamin D
supplementation for the following secondary outcomes:
a) specific viral infections including influenza, adenovirus
and respiratory syncytial virus (RSV); b) asthma exacerba-
tions in preschoolers with asthma or recurrent wheezing;
c) direct and indirect economic costs associated with
URTIs; d) vitamin D deficient serum levels as defined
by the AAP and CPS. We hypothesize that the likelihood
of these secondary outcomes will be lower in children
supplemented with 2000 IU/day of vitamin D.
Methods/design
Participants
The parents of healthy children aged 1 to 5 years pre-
senting to seven TARGet Kids! participating academic
pediatric or family medicine group practices in Toronto,
Canada for a scheduled well-child visit prior to viral sea-
son (September through November over four years) are
being approached to participate. Practices have between 3
and 10 practicing physicians. We are excluding children
with gestational age < 32 weeks as they are a high risk
population for respiratory tract infection and asthma, chil-
dren with chronic illness (except for asthma) on parentalreport which is known to interfere with vitamin D metab-
olism and increase the risk of respiratory infection, and
those children with a sibling participating in the study to
reduce clustering effects.
After parents of participating children provide in-
formed consent, baseline characteristics are obtained
using a parent-completed, standardized, data collection
form based on questions used in the Canadian Commu-
nity Health Survey (see Additional file 2: Baseline Data
Collection Form) [86]. The following data is being col-
lected: age, sex, birth weight, enrolment date, parents’
ethnicity, maternal age, education and health, duration
of breastfeeding, bottle use, current and past vitamin D
supplementation, dietary vitamin D intake using 3 day diet-
ary recall, daily multivitamin use, influenza immunization
status, screen viewing time, physical activity, outdoor time,
and sun exposure. In addition, height, weight and skin pig-
mentation are being measured using standardized tech-
niques. A venous blood sample is obtained to document
baseline 25-hydroxyvitamin D levels.
Study design
A multicentre pragmatic randomized controlled super-
iority trial is being conducted over four winters. As this
trial's primary goal is to inform health policy and sec-
ondarily to contribute to an explanation of the causal
relationship between vitamin D and child health out-
comes, this trial has been designed along the pragmatic
end of the pragmatic-explanatory continuum, as de-
scribed by KT (co-author) and other leading trial meth-
odologists [87]. Specifically, eligibility criteria, participant
compliance, follow-up intensity, and primary analysis are
following pragmatic approaches (“Does this intervention
work under usual conditions?”); whereas, follow-up of out-
comes are following approaches mid-way along the
pragmatic-explanatory continuum (“Can this intervention
work under ideal conditions?”). This protocol follows the
2013 SPIRIT guidelines (Defining Standard Protocol Items
for Randomized Trials) [88,89]. Trial results will be re-
ported according to the 2010 CONSORT guidelines for
pragmatic trials [90].
Intervention
Children are randomly assigned to one of two groups:
‘standard dose’ of 400 IU/day vitamin D or ‘high dose’ of
2000 IU/day vitamin D (see Figure 1). A drop-based for-
mulation (Kids Ddrops™ containing Vitamin D3) was
chosen to facilitate ease of administration to young chil-
dren. Parents of children in each group are instructed to
administer 1 drop of the provided solution to their child
by mouth once daily, at any time of day, each day from
the time of enrolment (September-November) through
the winter until follow-up (April-May) 4–8 months later.
As 25-hydroxyvitamin D levels are reported to stabilize
age 1-5 years
healthy
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Figure 1 DO IT! Trial Schematic.
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culate in Canada November through April [93], children
are recruited September through November. The duration
of the intervention (4–8 months) has been chosen to
mimic the routine practice of vitamin D supplementation
of preschoolers over the Canadian winter (see Table 1).
Concomitant interventions prohibited include over-the-
counter multivitamins which contain vitamin D, over-the-
counter vitamin D preparations and prescription vitamin
D. As this is a pragmatic trial, no specific strategies are in-
troduced to improve adherence. To monitor adherence at
the end of the trial, parents are asked to return bottles and
the amount of vitamin D administered is calculated based
on the volume of solution remaining [94]. No specific cri-
teria are being used for discontinuation or modification of
the interventions, as the doses of vitamin D are within the
safe and recommended dosages for children [70].
Block randomization occurs by study site with blocks
of varying sizes to ensure that group sizes are similar at
the end of each block [88]. This is particularly important
in a study of vitamin D and URTI, as date of enrolment
(time) may be an important covariate. Sequence gener-
ation stratified by practice site was performed centrally
at the Applied Health Research Centre (AHRC) at St.
Michael’s Hospital using a computer random number
generator; KT (biostatistician and co-author) generated
the allocation sequence. Parents, attending physicians,
laboratory personnel, and study personnel conducting
the outcome assessments, data analysts and investigators
are blind to the group allocation. Allocation concealment
is achieved by having the Pharmacy Department preparethe vitamin D preparations in sealed, serially numbered
bottles identical in appearance and weight, with the drops
similar in consistency and taste. Group allocation will be
concealed until the final data analysis is performed.
Outcomes and measures
The primary outcome is the number of laboratory-
confirmed viral URTIs per child over the winter months.
Because of the wide variety of respiratory viruses and
URTI illness presentations, signs and symptoms of viral
URTI are non-specific and may not be reliably measured
by parental report [95,96]. Therefore, in addition to par-
ents of enrolled children completing a symptom checklist
with each URTI (see Additional file 3: Symptom Check-
list), parents are asked to obtain a nasal swab from their
child. Nasal swabs done by parents have been shown to
be as effective in detecting respiratory viruses as those
obtained by health professionals but less invasive and
better tolerated [97]. Parents are instructed to place the
swab in provided viral transport media and refrigerate
until couriered to the study laboratory (Mount Sinai
Services) within 24 hours [44,98]. Respiratory viruses
are identified using reverse transcriptase polymerase chain
reaction (RT-PCR) technology. RT-PCR is performed on
each sample which has a sensitivity of 95% and specificity
of 100% for the identification of respiratory RNA vi-
ruses, which is more sensitive than viral culture and
comparable to immunofluorescence [99]. Samples are
tested for 18 common respiratory viruses including influ-
enza A and B, adenoviruses, respiratory syncytial virus
(RSV), picornaviruses (enteroviruses and rhinoviruses),
Table 1 Schedule of procedures, assessments, and interventions for the DO IT! Trial (based on the SPIRIT template)
Study period
Pre-randomization Intervention Post-intervention follow-up Close-out
TIMEPOINT Year 1 0 Year 1 Year 1
Sept – Nov Sept – March April – May
Year 2 Year 2 Year 2
Sept – Nov Sept – March April – May
Year 3 and 4 Year 3 and 4 Year 3 and 4 Year 4
Sept – Nov Sept – March April – May June – Aug
INTERVENTIONS:
‘Standard dose’ 400 IU/day X X
‘High dose’ 2000 IU/day X X
PROCEDURES:
Informed consent X
Eligibility screen X
Randomization X
ASSESSMENTS:
Baseline survey data X X
Anthropometrics X
25-hydroxyvitamin D serum level X X
Laboratory-confirmed URTI X
Asthma exacerbations X
Follow-up survey data X
ANALYSIS X
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using the ID-Tag™ RVP assay using the Luminex xMAP™
system (Cat# R019A0105, TM Bioscience Corp., Toronto,
ON) [100]. This is the same assay and machine that is
routinely used in the Ontario public health laboratories.
Secondary outcomes include parent reported URTI,
specific viral agents that cause URTI (influenza, adeno-
virus and RSV), asthma exacerbations among children with
asthma, physician-diagnosed otitis media and pneumonia,
emergency department visits and hospitalizations, collected
by monthly telephone call and confirmed by review of the
child’s clinic medical record. Follow-up 25-hydroxyvitamin
D serum level is measured to determine the vitamin D
dose vs. serum response relationship. Finally, change in 25-
hydroxyvitamin D serum level from baseline is determined
to document that an improvement in health outcomes is
mediated through an increase in 25-hydroxyvitamin D
serum level.
Parent reported URTI symptoms are defined as two or
more of fever (>38°C), cough, runny nose, sore throat,
headache, vomiting, feels unwell, muscle aches, ear ache
or infection, poor appetite, not sleeping well, cranky/fussy,
low energy or crying more than usual from a validated
parent completed symptom checklist (CARIFS) collected
with the viral sample. CARIFS has been developed,validated and extensively used by our team and others
[101,102]. A new URTI cannot commence until ≥ 3 symp-
tom free days since the end of a previous URTI [44].
Asthma is defined as parental report of asthma plus
confirmation from the child’s medical record of 2 or more
episodes of wheeze requiring the prescription of inhaled
asthma controlling medications [103]. An asthma exacer-
bation is defined as a wheezing episode in children with
asthma as obtained from parent completed symptom
checklist based on the International Study of Asthma and
Allergies in Childhood (ISAAC) [103].
Blood is drawn by trained pediatric phlebotomists from
the antecubital vein for determination of 25-hydroxyvitamin
D serum levels. Specimens are sent to the Clinical Bio-
chemistry Laboratory at the Mount Sinai Hospital with
the study requisition, where they are processed according
to standard procedures. Total 25-hydroxyvitamin D is
measured from serum samples using a competitive two-
step chemiluminescence assay which has been validated
for measurement of 25-hydroxyvitamin D in children
older than 1 year of age [104]. The specific instrument that
is used to analyze all samples is a Diasorin LIAISON® 25-
hydroxyvitamin D TOTAL [105]. This technique and in-
strument have been chosen to be consistent with national
vitamin D surveys from both Canada and the United
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machine has been performed and has demonstrated an
intraassay imprecision of 7.2% at a concentration of
213 nmol/L and an interassay imprecision of 4.9% at
32 nmol/L, 8.9% at 77 nmol/L and 17.4% at 213 nmol/L,
values which are well within acceptable limits for bio-
chemical measurements. During this study, the instru-
ment is monitored using the UK DEQUAS external
quality assessment scheme which is an internationally
recognized vitamin D quality assessment protocol [106].Recruitment and retention
Since June 2008, over 4500 children age 1–5 years have
been recruited through TARGet Kids! practices with col-
lection of questionnaires (demographics, lifestyle factors)
and anthropometric measures (height, weight and waist
circumference). Since December 2008 venous blood sam-
ples have been collected from over 2500 children [107].
TARGet Kids! is now operating out of seven sites with over
100 children per month being recruited with phlebot-
omy. Therefore, recruitment of 750 children in September
through November over 4 consecutive seasons for this
study is feasible.
We expect that there will be a different spectrum of
infections as respiratory virus incidence, distribution and
severity tend to vary from year to year.
Strategies to achieve adequate recruitment include ap-
proaching eligible subjects during a well-child visit. Lists
of children scheduled for a well-child visit are reviewed
in advance. An information package is mailed to each
family 2 to 4 weeks prior to the visit inviting them to
participate. This allows parents time for consideration in
advance and reduce coercion to participate. Parents are
approached in person by the research assistant while
registering for the clinic visit. At the initial visit, baseline
survey data, anthropometric measures, and baseline vita-
min D serum level are collected.
Strategies for retention include a monthly telephone
call to encourage collection of nasal swabs and completion
of symptom checklists. Every reasonable attempt is made
to locate patients at follow-up. Topical anesthetic cream
(EMLA or Ametop) is offered to minimize discomfort
from venipuncture. Blood is drawn in the primary care
physician’s office negating the need to attend a separate la-
boratory visit. Parents who have moved out of district are
offered to visit The Hospital for Sick Children for repeat
laboratory testing. Should these efforts fail to obtain a
blood sample, a home visit for phlebotomy is offered. This
is expected to occur in less than 10% of subjects.Follow-up data collection and data management
Parents of participating children receive a monthly tele-
phone call by a research assistant reminding them toadminister the vitamin D supplement daily and record
the number of asthma exacerbations, emergency depart-
ment visits, hospitalizations and missed work days. Par-
ents are also be reminded to collect nasal swabs and
complete symptom checklists. In addition, parents are
asked to return to their child’s physician’s office in April
or May to capture peak respiratory virus season. At the
follow-up visit, blood is drawn for 25-hydroxyvitamin D
level and a follow-up data collection form completed.
The following potential co-interventions are also mea-
sured: influenza vaccination, dietary vitamin D intake
using a 3 day dietary recall [86], over-the-counter vita-
min and mineral supplementation (i.e., calcium contain-
ing multivitamins), herbal remedies (i.e., echinacea) and
hours per week in daycare (see Additional file 4: Follow-
up Data Collection Form). This methodology has been
used successfully by our group and others [44,45,98].
To ensure high quality data collection, research assis-
tants are trained in the accurate completion of question-
naires, anthropometric measurement and are registered
pediatric phlebotomists as per standard TARGet Kids!
operating protocol. Weight is measured using a preci-
sion digital scale (±0.025% SECA, Hamburg Germany),
standing height is measured using a stadiometer (SECA,
Hamburg Germany), and skin pigmentation is measured
using a narrow-band reflectometer (Dermaspectrometer,
Cortex Technology) [108-111]. Questionnaires and URTI
symptom checklists have been pilot tested to ensure under-
standability and reduce incomplete responses [101]. Col-
lected data is electronically entered on a daily basis by
research assistants at each site into the study’s central
database via a secure web-based data portal.
The Applied Health Research Centre (AHRC) of the
Keenan Research Centre, Li Ka Shing Knowledge Institute
of St. Michael’s Hospital houses this central database
and is the data management centre for this study
(under the direction of MM, co-author). AHRC em-
ploys state-of-the art web-based data management soft-
ware: Medidata RAVE™ (5.6.3) by Medidata Solutions
Inc. RAVE™ uses secure encrypted web-based data cap-
ture technology and is the data repository for data col-
lected during this study. RAVE™ is an industry-leading
electronic data capture and clinical data management
system, with user configurable workflows, sophisticated
case report form (CRF) design, complex edit checking,
and customized security parameters. RAVE™ allows our
research assistants to enter data remotely in real time
to the central database from any of the practice sites.
RAVE™ has extensive built in reporting capabilities, and
data can be exported to standard formats for data ana-
lysis (e.g., SAS). Laboratory tests are directly uploaded
to RAVE™ through a secure web portal. These features
enable TARGet Kids! to be highly efficient and are vital
to the success of this study.
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The sample size was based on asymptotic methods for a
likelihood ratio test assuming a Poisson distributed out-
come and was confirmed by simulation studies. All sample
size and power calculations assume a 5% Type I error
probability (two-sided). If we assume an average of one
URTI per month during a minimum of 4 winter months
[42,44-49] among children receiving the standard dose of
vitamin D, we would therefore expect an average of four
URTI per child over the winter. A sample size of 300 per
group would give 90% power to detect a reduction in
the average number of URTI per winter of one URTI.
We believe that, even one fewer URTI over the winter
would be a clinically important outcome, especially to
families with young children. Although the study is not
powered to detect reductions of specific kinds of infec-
tions, a conservative estimate is that at least 25% of chil-
dren will have one of RSV, adenovirus or influenza which
collectively result in the greatest burden of illness in this
population [44,50], this sample size gives 80% power to
detect a 50% absolute reduction in this composite out-
come. Preliminary TARGet Kids! data suggests an 80%
retention rate [107,112]; therefore, to accommodate a
20% loss to follow-up, 375 children will be recruited to
each group (750 total).
Statistical analysis
Baseline characteristics will be summarized by appropriate
descriptive statistics. Although randomization is expected
to balance the covariates, variables that demonstrate, by
chance, a potentially clinically meaningful imbalance, will
be considered as possible adjusting covariates.
All outcomes will be analyzed following the intention-
to-treat principle [113]. The primary analysis of the pri-
mary outcome will assess the effect of vitamin D supple-
mentation on laboratory-confirmed URTI. Mean URTI
rates (per child) will be computed for each group. A Poisson
regression model will be used to make the statistical com-
parison between the groups. Variable length of follow-up
time will be accounted for by using a suitable offset
(logarithm of observation duration) in the Poisson model. If
there is evidence of overdispersion, a negative-binomial
model may be considered. The secondary analysis of the
primary outcome will use survival methods to examine time
to first URTI and the Andersen-Gill extension of the Cox
model to analyze recurrent URTI events [114]. The ration-
ale for conducting the trial over four seasons is to increase
the chance of a sufficiently active viral season to assess a
protective effect of the intervention. This will also allow us
to examine the consistency of the effect over the four
seasons as strains of viruses vary from year to year.
Analysis of secondary outcomes will use standard
methods for continuous data (i.e., vitamin D level) using
means, ANOVA and linear regression with and withoutadjustment for baseline group differences. The incidence
of binomial secondary outcomes such as specific viral
infections will be summarized descriptively. Since the inci-
dence of some infections may be low, logistic regression
analyses will only be performed to assess the treatment ef-
fect when there are sufficient events (over 30). Subgroup
analyses will be conducted for children with asthma. Fre-
quency of asthma exacerbations will be analyzed using the
same methods as those used for the primary outcome.
Economic analysis
A cost-effectiveness analyses will be conducted using data
from this trial. A societal perspective will be employed to
calculate both direct health service utilization costs as well
as indirect costs to families of an URTI. The time horizon
of the analysis will be limited to the follow-up of this trial
in order to leverage direct data. Given the short time hori-
zon, discounting of costs and outcomes will not be ap-
plied. This analysis will include the cost of ‘high dose’
vitamin D supplementation, physician visits, medications
(antimicrobial and over-the-counter), hospital admissions,
emergency department visits and laboratory testing ab-
stracted from the child’s medical record and costs associ-
ated with lost income from parental work absenteeism
and time out of daycare obtained by monthly telephone
call using previously described techniques [45,74,115].
Standard, publicly available costing sources will be used to
cost resource utilization parameters. Specifically, we will
use cost sources such as the Ontario Health Insurance
Programs (OHIP), Ontario Case Costing Initiative (OCCI)
and standard Ministry of Health (MOH) reimburse-
ments for diagnostic tests. Sex-weighted hourly wage rate
will be derived from Statistics Canada Data. The cost-
effectiveness analysis will estimate the cost per laboratory-
confirmed URTI avoided. The net benefit regression
approach will be used to determine each patient’s net
benefit from treatment (NBi) based upon the data col-
lected on resource use and lost parental productivity
[116]. Graphs will be used to illustrate the incremental net
benefit assuming varying willingness to pay. Each estimate
of net benefit will be adjusted for potential confounders
through regression. In its simplest form, net benefit re-
gression involves fitting the following simple linear regres-
sion model: NBi = β0 + βTXTXi + εi where TXi is the i
th
person’s treatment indicator (TXi = 1 for new treatment
and 0 for usual care) and εi is a stochastic error term
[117]. Parametric confidence intervals for incremental net
benefit will be compared to results of non-parametric
bootstrapping to characterize statistical uncertainty in the
economic analysis.
Ethical considerations
This study was granted ethics approval by The Hospital
for Sick Children Research Ethics Board (REB File No.:
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approved by the REB for one year ending in September
2015. This study has been registered as a clinical trial
(www.clinicaltrials.gov, ID NCT01419262). Written in-
formed consent will be obtained from parents of all child
participants prior to any data collection (see Additional
file 5: Consent Form). Parents will benefit by the provision
of 4–8 months of vitamin D supplementation for their
child free of charge. Children may directly benefit via the
identification of viral etiology for URTI symptoms and
through identification of vitamin D deficiency. The child’s
pediatrician will receive viral test results as well as blood
results and manage their patient according to national
clinical guidelines [5]. While a placebo arm may be eth-
ically justified given the lack of evidence supporting
improved health outcomes with supplementation, it is
unlikely to be feasible given that current AAP vitamin D
guidelines recommend vitamin D supplementation for
children older than 1 year and the majority of families in
our population are following this recommendation [4,29].
A data safety and monitoring board (DSMB) was
established and is composed of a pediatrician, an endo-
crinologist, an infectious disease expert and a biostatis-
tician and is responsible for monitoring of adverse
events. All adverse events will be graded for severity
(mild to life threatening) and assessed for relationship
to the study intervention. The DSMB (which will be
blinded to group allocation) will review safety data be-
tween years 1 and 2 and will make decisions regarding
unblinding of study groups and premature trial termin-
ation. As vitamin D dosages in this study are within the
Tolerable Upper Intake Level as recommended by
Health Canada for children older than 1 year of age
(2500 IU per day for children 1–3 years and 3000 IU/day
for children 4–8 years), risk of vitamin D excess is low
[70]. In addition, other studies which have used vitamin D
doses of up to 50,000 IU per week in children did not
show evidence of vitamin D toxicity [118,119]. However,
we will monitor for adverse events by ensuring that our
participating physicians are aware of signs and symptoms
of vitamin D toxicity including nephrolithiasis and hyper-
calcemia. Additionally, each participant will be assessed
for vitamin D toxicity at follow-up through measurement
of serum calcium, alkaline phosphatase and parathyroid
hormone [6,120,121].
Knowledge translation
Findings from this research will be disseminated directly
to the physician participants and their patients. We will
share our results at the annual meeting of all the TARGet
Kids! practices (physicians, nurses, office staff ), research
team (investigators, research assistants, students), and
policy leaders (representatives from Section of Commu-
nity Paediatrics, Family and Community Practice, OntarioMedical Association, and parent representatives). Down-
stream dissemination to primary care physicians will occur
through formal and informal venues at local levels, such
as City Wide Paediatric Rounds, The Hospital for Sick
Children Paediatric Update and those held by local phy-
sician groups. The results of this study will be shared with
the academic community through peer-review publications
and presentations at national and international conferences,
locally through hospital rounds and presentations, and
through our website http://www.targetkids.ca/. Messages
will be relevant to professionals working in the fields of
pediatrics, family medicine, endocrinology, infectious dis-
ease, nursing, dietetics, and public health. We will also
share our findings with colleagues at the Ontario Agency
for Health Protection and Promotion, the Centre for Effect-
ive Practice, the Maternal Infant Child and Youth Research
Network (MICYRN), the Ontario Medical Association, the
Canadian Paediatric Society and the American Academy of
Pediatrics. Opportunities for media coverage will be sought
using an experienced knowledge broker.
Discussion
There is compelling evidence that young children in North
America have vitamin D levels significantly lower than ex-
perts recommend. Basic science and epidemiological stu-
dies make the case that low wintertime vitamin D levels
may be related to two common and costly child health out-
comes: wintertime viral URTI and asthma exacerbations.
The DO IT Trial is the first randomized controlled trial to
investigate vitamin D related respiratory health outcomes
in preschoolers. The results of this trial will make an imme-
diate contribution by defining clinical practice standards for
vitamin D supplementation for young children and provide
an evidence base for national vitamin D guidelines.
The key strengths of this study protocol include a
novel and important research question, the outcome of
which could affect nearly every young child in Canada,
rigorous methodology and an implementation strategy
that leverages the efficiency of the only primary care
research platform for young children in Canada: TARGet
Kids!. The TARGet Kids! infrastructure and collaborations
between child health researchers at the St. Michael’s
Hospital, The Hospital for Sick Children and community
health care providers make this team unique in Canada
and position it ideally to carry out this trial on vitamin D
supplementation of Canadian preschoolers and provides
opportunity for truly integrated knowledge translation.
Furthermore, a solid interdisciplinary team of primary care
practitioners and highly qualified methodologists has been
assembled with established expertise in preventive child
health research, vitamin D deficiency, infectious diseases, la-
boratory medicine, health economics, clinical epidemiology
and clinical trials methodology, analysis and data manage-
ment to conduct this much-needed research.
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regarding wintertime vitamin D supplementation and
important health outcomes in Canadian children. Potential
downstream economic and health benefits of this trial to
Canadian children, the health care system and society in-
clude reduced population wide morbidity and associated
health care and societal costs. The current paper serves as
an important step in the dissemination of the DO IT! Trial
by outlining the study background, explaining some
of the methodological considerations, and providing a
detailed description of methods prior to reporting the
results of the analyses.
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